Sansure Biotech released its 2026 interim report. Total operating revenue was 834 million yuan, down 3.95% from the same period last year. Net profit attributable to the parent company was 98.02 million yuan, down 39.76% year on year. Net cash flow from operating activities was negative 15.66 million yuan, ranking 78th among disclosed peer companies. The company's latest asset-liability ratio was 26.59%, gross margin was 71.32%, return on equity was 1.40%, and diluted earnings per share was 0.17 yuan. The company had 20,900 shareholders, and the top ten shareholders held 298 million shares, accounting for 51.41% of total share capital.
Sansure Biotech IncNet profit down 39.76% and operating cash flow negative in interim report.
